Clinical Trials on Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed in Singapore
Total 7 results
-
National Cancer Centre, SingaporeMSD Pharma (Singapore) Pte LtdRecruitingHormone Receptor-Positive HER2-Negative Advanced Breast CancerSingapore
-
National University Hospital, SingaporeAdagene IncRecruitingAdvanced Solid Tumor | HER2-negative Breast CancerSingapore
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast CancerFrance, Italy, Germany, Singapore, Sweden, Spain, United Kingdom, United States
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore